0001193125-23-079299.txt : 20230324 0001193125-23-079299.hdr.sgml : 20230324 20230324172955 ACCESSION NUMBER: 0001193125-23-079299 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230324 DATE AS OF CHANGE: 20230324 EFFECTIVENESS DATE: 20230324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 23760892 BUSINESS ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92037 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92037 15-12G 1 d452175d1512g.htm 15-12G 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-39512

 

 

Metacrine, Inc.

(Exact name of registrant as specified in its charter)

 

 

4225 Executive Square, Suite 600

San Diego, California 92037

(858) 369-7800

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   ☒

Rule 12g-4(a)(2)

   ☐

Rule 12h-3(b)(1)(i)

   ☒

Rule 12h-3(b)(1)(ii)

   ☐

Rule 15d-6

   ☐

Rule 15d-22(b)

   ☐

Approximate number of holders of record as of the certification or notice date: 34

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Metacrine, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

    METACRINE, INC.
Date: March 24, 2023     By:  

/s/ Michael York

    Name:   Michael York
    Title:   President and Chief Executive Officer